KIT protein expression and mutational status of KIT gene in pituitary adenomas

摘要: KIT protein expression and mutational status of gene in different types tumours have been intensively studied since Imatinib Mesylate, KIT/PDGFRA tyrosine kinase inhibitor became available. However, only one immunohistochemical study on pituitary adenomas has published. There are currently no reports adenomas. We immunohistochemically investigated 252 found cytoplasmic reactivity 52.4% membranous 8.3% all was statistically significant difference between clinically non-functioning, growth hormone- adrenocorticotroph hormone-producing The group with dominated by somatotropinomas non-functioning a subset also confirmed western blot analysis 48 Immunohistochemical correlated basic clinical data cohort acromegalic patients additional (somatostatin receptor type 2A expression, response to somatostatin analogue treatment gsp oncogene). Exons 9, 11, 13 17 were searched for mutations the minority using denaturing high-performance liquid chromatography suspected cases sequencing or more exons. No examined exons found. Our results may suggest role pathogenesis point out need further research find if KIT-reactive could be sensitive Mesylate.